Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 2, 2015, Pages 288-301

  Goldstein, Robert ^a   Sosabowski, Jane ^c   Livanos, Maria ^a   Leyton, Julius ^c   Vigor, Kim ^e   Bhavsar, Gaurav ^a   Nagy Davidescu, Gabriela ^d   Rashid, Mohammed ^a   Miranda, Enrique ^a   Yeung, Jenny ^a,b   Tolner, Berend ^a   Plückthun, Andreas ^d   Mather, Stephen ^c   Meyer, Tim ^a   Chester, Kerry ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Breast cancer; DARPin; HER2; Molecular imaging; SPECT

Indexed keywords

CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEXAHISTIDINE ANKYRIN REPEAT PROTEIN DARPIN G3 I 125; HEXAHISTIDINE GLUTAMATE ANKYRIN REPEAT PROTEIN DARPIN G3 I 111; HISTIDINE GLUTAMATE ANKYRIN REPEAT PROTEIN DARPIN G3 I 111; HISTIDINE GLUTAMATE ANKYRIN REPEAT PROTEIN DARPIN G3 I 125; RADIOLIGAND; TETRAXETAN; TRASTUZUMAB; UNCLASSIFIED DRUG; ANKYRIN; COORDINATION COMPOUND; HYBRID PROTEIN; INDIUM; PROTEIN BINDING; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST TUMOR; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CT-SPECT SCANNER; DRUG DISTRIBUTION; DRUG SPECIFICITY; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; ISOTOPE LABELING; KOMAGATAELLA PASTORIS; MOLECULAR IMAGING; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; RADIOACTIVITY; RADIOCHEMISTRY; SEQUENCE TAGGED SITE; SERUM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; TUMOUR TO BLOOD RATIO; ANIMAL; BAGG ALBINO MOUSE; EXPERIMENTAL MAMMARY NEOPLASM; METABOLISM; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; ANKYRIN REPEAT; CELL LINE, TUMOR; COORDINATION COMPLEXES; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84925500414     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2940-2     Document Type: Article

References (41)

1. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9:16–32. doi:10.1038/nrclinonc.2011.177.
2. Ross JS. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News Perspect. 2009;22:93–106. doi:10.1358/dnp.2009.22.2.1334452.
3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97. doi:10.1016/S0140-6736(10)61121-X.
4. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91. doi:10.1056/NEJMoa1209124.
5. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013. doi:10.1200/JCO.2013.50.9984.
6. Goldstein R, Sosabowski J, Vigor K, Chester K, Meyer T. Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer. Expert Rev Anticancer Ther. 2013;13:359–73. doi:10.1586/era.13.11.
7. Turner NH, Di Leo A. HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact. Cancer Treat Rev. 2013;39:947–57. doi:10.1016/j.ctrv.2013.05.003.
8. Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30:2601–8. doi:10.1200/JCO.2011.37.2482.
9. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol. 2002;13:1036–43.
10. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19. doi:10.1056/NEJMoa1113216.
11. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358:1409–11. doi:10.1056/NEJMc0801440.
12. Mortimer JE, Bading JR, Colcher DM, Conti PS, Frankel PH, Carroll MI, et al. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using 64Cu-DOTA-trastuzumab PET. J Nucl Med. 2013;55:23–9. doi:10.2967/jnumed.113.122630.
13. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586–92. doi:10.1038/clpt.2010.12.
14. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276–82. doi:10.1200/JCO.2005.03.8448.
15. Sorensen J, Sandberg D, Sandstrom M, Wennborg A, Feldwisch J, Tolmachev V, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med. 2014;55:730–5. doi:10.2967/jnumed.113.131243.
16. Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, Forrer P, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol. 2004;22:575–82. doi:10.1038/nbt962.
17. Boersma YL, Pluckthun A. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol. 2011;22:849–57. doi:10.1016/j.copbio.2011.06.004.
18. Binz HK, Stumpp MT, Forrer P, Amstutz P, Pluckthun A. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol. 2003;332:489–503.
19. Schilling J, Schoppe J, Pluckthun A. From DARPins to LoopDARPins: novel LoopDARPin design allows the selection of low picomolar binders in a single round of ribosome display. J Mol Biol. 2014;426:691–721. doi:10.1016/j.jmb.2013.10.026.
20. Dreier B, Pluckthun A. Rapid selection of high-affinity binders using ribosome display. Methods Mol Biol. 2012;805:261–86. doi:10.1007/978-1-61779-379-0_15.
21. Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-Davidescu G, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res. 2010;70:1595–605. doi:10.1158/0008-5472.CAN-09-2724.
22. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, McKern NM, et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol. 2007;369:1015–28. doi:10.1016/j.jmb.2007.03.028.
23. Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, Pluckthun A. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure. 2013;21:1979–91. doi:10.1016/j.str.2013.08.020.
24. Hofstrom C, Orlova A, Altai M, Wangsell F, Graslund T, Tolmachev V. Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I. J Med Chem. 2011;54:3817–26. doi:10.1021/jm200065e.
25. Hofstrom C, Altai M, Honarvar H, Strand J, Malmberg J, Hosseinimehr SJ, et al. HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules. J Med Chem. 2013;56:4966–74. doi:10.1021/jm400218y.
26. Sosabowski JK, Matzow T, Foster JM, Finucane C, Ellison D, Watson SA, et al. Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide. J Nucl Med. 2009;50:2082–9. doi:10.2967/jnumed.109.064808.
27. Waibel R, Alberto R, Willuda J, Finnern R, Schibli R, Stichelberger A, et al. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol. 1999;17:897–901. doi:10.1038/12890.
28. Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974–81. doi:10.2967/jnumed.108.060392.
29. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:701–6. doi:10.1038/nbt968.
30. Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, et al. Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res. 2011;17:1509–20. doi:10.1158/1078-0432.CCR-10-1654.
31. Perols A, Honarvar H, Strand J, Selvaraju R, Orlova A, Karlstrom AE, et al. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules. Bioconjug Chem. 2012;23:1661–70. doi:10.1021/bc3002369.
32. Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, Sandstrom M, et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007;67:2178–86. doi:10.1158/0008-5472.CAN-06-2887.
33. Sosabowsky J, Melendez-Alafort L, Mather S. Radiolabelling of peptides for diagnosis and therapy of non-oncological diseases. Q J Nucl Med. 2003;47:223–37.
34. Pruszynski M, Koumarianou E, Vaidyanathan G, Revets H, Devoogdt N, Lahoutte T, et al. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med. 2014;55:650–6. doi:10.2967/jnumed.113.127100.
35. Epa VC, Dolezal O, Doughty L, Xiao X, Jost C, Pluckthun A, et al. Structural model for the interaction of a designed ankyrin repeat protein with the human epidermal growth factor receptor 2. PLoS One. 2013;8:e59163. doi:10.1371/journal.pone.0059163.
36. Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17:1–12. doi:10.1007/s10120-013-0252-z.
37. Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, et al. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response – implications for radionuclide therapy. J Nucl Med. 2008;49:1884–99. doi:10.2967/jnumed.108.053173.
38. Beylergil V, Morris PG, Smith-Jones PM, Modi S, Solit D, Hudis CA, et al. Pilot study of 68Ga-DOTA-F(ab’)2-trastuzumab in patients with breast cancer. Nucl Med Commun. 2013;34:1157–65. doi:10.1097/MNM.0b013e328365d99b.
39. Baum RP, Prasad V, Muller D, Schuchardt C, Orlova A, Wennborg A, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med. 2010;51:892–7. doi:10.2967/jnumed.109.073239.
40. Tolner B, Bhavsar G, Foster B, Vigor K, Chester K. Production of recombinant proteins from Pichia pastoris: interfacing fermentation and immobilized metal ion affinity chromatography. In: Gupta VK, Tuohy MG, O’Donovan A, editors. Laboratory protocols in fungal biology. Current methods in fungal biology. New York: Springer; 2013; p. 407–420
41. Han BH, Xiu QY, Wang HM, Shen J, Gu AQ, Luo Y, et al. A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC). Zhonghua Zhong Liu Za Zhi. 2011;33:854–9.